A specialty biopharmaceutical company centered on allergy.

This study is the first to test Circassia’s novel room-temperature-stable ToleroMune formulation. This presents great potential practical advantages weighed against existing allergy desensitisation remedies, which are unstable and require cold chain distribution and storage inherently. During the study, the volunteers will be exposed to aerosolised cat dander in an environmental exposure chamber, both before and after treatment, to measure the effect of the ToleroMune T-cell vaccine. An interview with Dr Matt SilverJumping genes: a marker for early cancer medical diagnosis? An interview with Dr Kazazian Circassia in addition has initiated the first scientific research of its T-cell vaccine against home dust mite allergy, which is normally in Quebec underway, Canada. The double-blind, placebo-controlled, randomised trial shall include 50 allergy patients.The tumor cells are cultured with the dendritic cells in the laboratory to enable the immune cells to recognize cancers cells as targets. When the resulting ‘specialised’ dendritic cells are injected back to the patient, they seek out remaining tumor cells and signal for the T lymphocytes to destroy them.. Clinical data of Trovagene’s Precision Cancer Monitoring platform to be presented at two medical conferences Trovagene, Inc. , a programmer of cell-free of charge molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM system will be offered at the 2015 Cancer Markers and Liquid Biopsies meeting in San Diego, On June 11-12 CA, and at the AACR Accuracy Medication Series: Integrating Clinical Genomics and Cancers Therapy in Salt Lake City, UT on June 13-16.